

POSTER ABSTRACT INDEX

POSTER #	ABSTRACT & AUTHORS	PAGE
1	Surveillance of Mucorales resistance to azoles in the waste sorting industry: assessment of filtering respiratory protective devices and gloves LA Caetano*, M Dias, B Almeida, C Viegas	65
2	<i>Aspergillus</i> spp. and azole-resistance characterization on filtering respiratory protective devices from waste sorting industry C Viegas*, M Dias, B Almeida, P Gonçalves, C Verissimo, R Sabino, L Aranha Caetano	66
3	Antifungal susceptibility testing of clinical and hospital <i>Aspergillus</i> isolates at the nephrology ward of an Iranian training hospital K Diba*, H Fakhim, K Makhdoomi, N Javanmard, S Javanmard	67
4	Azole- and amphotericin B-resistant <i>Aspergillus fumigatus</i> strains isolated from clinical specimens and environment in Azerbaijan RM Huseynov*, SS Javadov, AA Kadyrova, B Bozdogan, E Oryashin, SM Askarova, BT Taqiyev, I Karalti, D Denning	68
5	<i>Hmg1</i> gene mutation in triazole-resistant <i>Aspergillus fumigatus</i> clinical isolates without <i>cyp51A</i> gene mutations T Colley*, P Strong, G Rapeport, K Ito	70
6	Emergence of azole resistant <i>Aspergillus</i> species: a consequence of environmental exposure to azole pesticides in agricultural fields of North India P Sen*, Mukund, M Vermani, J Shankar, P Vijayaraghavan	72
7	Isoeugenol as a potential antifungal molecule against azole resistant environmental isolates of <i>Aspergillus fumigatus</i> and their biofilm L Gupta*, P Sen, P Vijayaraghavan	73
8	Point mutations in the 14α-sterol demethylase Cyp51A or Cyp51C could contribute to azole resistance in <i>Aspergillus flavus</i> J Lucio*, I Gonzalez-Jimenez, O Rivero-Menendez, A Alastruey-Izquierdo, T Pelaez, L Alcazar-Fuoli, E Mellado	74
9	Antifungal activity of novel triazole, efinaconazole, and nine comparators against 354 molecularly identified <i>Aspergillus</i> isolates, <i>in vitro</i> H Badali*, Z Taheri Rizi, M Abastabar, M Ilkit, JF Meis, MM Davoudi	75
10	Susceptibility profile of Mucoralean fungi isolated from the United States to current antifungal drugs H Badali*, C Gibas, D McCarthy, H Patterson, C Sanders, J Mele, H Fan, N.P Wiederhold	76
11	Clinical <i>Aspergillus</i> isolates causing aspergillosis in the last 20 years: an overview of aetiology and antifungal resistance to azoles and amphotericin B J Serrano*, E Reigadas, A Vena, M Machado, P Muñoz, P Escribano, J Guinea	78
12	Susceptibility patterns of contemporary <i>Aspergillus fumigatus</i> isolates from the United States to azole antifungals N Wiederhold*, H Badali, D McCarthy, H Patterson, C Sanders, J Mele, H Fan, C Gibas	80
13	Elucidating echinocandin resistance mechanisms in <i>Mucor circinelloides</i> A Garcia*, EY Huh, SC Lee	82

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER #	ABSTRACT & AUTHORS	PAGE
14	The role of pentraxin-3 in the immunometabolic regulation of antifungal immunity D Antunes*, V Aimaniananda, C Duarte-Oliveira, SM Gonçalves, C Cunha, T Gonçalves, A Carvalho	83
15	Genome Wide Association Study (GWAS) for antifungal sensitivity in the opportunistic pathogen <i>Aspergillus fumigatus</i> S Zhao*, JR Fortwendel, A Watanabe, JG Gibbons	84
16	CRISPR / Cas9 genome editing technology to verify the contribution of known mutations in the <i>cyp51A</i> gene and its promoter to azole resistance in <i>Aspergillus fumigatus</i> T Umeyama*, T Inukai, M Tateno, S Yamagoe, S Takatsuka, Y Hoshino, K Ishino, Y Miyazaki	85
17	Hmg1 mutation conferring multi-azole resistance in <i>Aspergillus fumigatus</i> T Arai*, T Umeyama, T Inukai, A Watanabe, Y Miyazaki, K Kamei	86
18	CLSI versus EUCAST for azoles susceptibility - the necessity to unify D Pinheiro*, C Monteiro, M Maia, E Pinto	87
19	Antifungal susceptibility testing of clinical and community environment isolates of <i>Aspergillus</i> species J Chander*, N Singla, M Kaur, D Aggarwal2	88
20	<i>In vitro</i> evaluation of combination of Ibrexafungerp and azoles against <i>Aspergillus</i> spp. isolated from lung transplant recipients V Jagadeesan, E Driscoll, B Hao, S Barat, K Borroto-Esoda, D Angulo, C Clancy, M Nguyen*	89
21	D430G mutation of CYP51A in <i>Aspergillus fumigatus</i> causes azole-resistance H Majima, A Teppe, A Watanabe*, K Kamei	90
22	Antimicrobial susceptibility of <i>Aspergillus fumigatus</i> and <i>Stenotrophomonas maltophilia</i> biofilms: did they find strength in unity? L Roisin*, E Melloul, PL Woerther, J Guillot, E Dannaoui, F Botterel	91
23	Evaluation of drug susceptibility of <i>Aspergillus</i> species isolated from ICU of hospitals <i>in vitro</i> Ayat Nasrollahi Omran*	92
24	Mutations in <i>A. fumigatus</i> hmg1 which confer triazole resistance also alter sterol composition and increase multi-drug efflux pump gene expression JM Rybak*, W Ge, JE Parker, SL Kelly, NP Wiederhold, VM Bruno, PD Rogers, JR Fortwendel	93
25	Activity of diphenyl diselenide against <i>Aspergillus</i> isolates AM Melo*, VR Poester, L Munhoz, M Trápaga, B Roca, GB Klafke, RF Sabino, DA Stevens, MO Xavier	94
26	Molecular identification of <i>Aspergillus</i> isolates from Magellanic penguins AM Melo*, RP Silva-Filho, VR Poester, A von Grol, RF Sabino, DA Stevens, MO Xavier	95
27	<i>In vitro</i> and <i>in vivo</i> activity of manogepix/fosmanogepix, a novel antifungal with activity against <i>Aspergillus</i> and rare molds MD Huband, AS Ibrahim, T Gebremariam, DR Andes, PA Bien, KJ Shaw, MR Hodges*	96
28	Study and characterization of azole resistance in <i>Aspergillus</i> section <i>Nigri</i> A Pérez-Cantero*, A Martin-Vicente, L López-Fernández, J Guarro, JR Fortwendel, J Capilla	98

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER #	ABSTRACT & AUTHORS	PAGE
29	Does monitoring cyp51A-mediated triazole resistance in <i>Aspergillus fumigatus</i> by pyrosequencing lead to patient benefit? L Novak-Frazer*, D Hassan, S Hill, CB Moore, M Walczak, R Rautemaa-Richardson, MD Richardson	99
30	Azole resistant <i>Aspergillus fumigatus</i> from agricultural settings M Momany*, M Brewer, SE Kang, LG Sumabat, T Melie, B Mangum	100
31	The role of PTX3 in innate regulation of antifungal immunity in chronic pulmonary aspergillosis C Duarte-Oliveira*, S Ferreira, SM Gonçalves, D Antunes, A Mantovani, C Cunha, A Carvalho	101
32	Antifungal susceptibility profiles of olorofim (formerly F901318), and currently available systemic antifungals against mold and yeast phases of <i>Talaromyces marneffeii</i> J Zhang*, HF Liu, LY Xi, YC Chang, KJ Kwon-Chung, S Seyedmousavi	102
33	Synergic anti-fungal activity of topical PC945, a novel inhaled azole, with systemic echinocandin on <i>Aspergillus fumigatus</i> in vitro human alveoli model L Daly*, KA Lucas, T Colley, P Strong, G Rapeport, K Ito	103
34	Altered <i>A. fumigatus</i> cell wall integrity by PC945, a novel inhaled azole D Armstrong-James*, T Colley, P Strong, G Rapeport, K Ito <i>NOTE: This abstract has also been selected for Oral Presentation</i>	104
35	Neutrophil ROS controls fungal growth and inflammation in phagocyte NADPH oxidase-deficient zebrafish TJ Schoen*, EE Rosowski, BP Knox, NP Keller, A Huttenlocher	105
36	In vivo and in vitro impairment of Th cell and neutrophil responses against <i>Mucor irregularis</i> in Card9 knockout mice LY Sun*, Z Wan, RY Li, J Yu	106
37	Modulation of TREM1 signaling in macrophages infected with <i>Aspergillus fumigatus</i> I González-Jiménez*, M Jerónimo-Albaladejo, L Bernal-Martínez, E Mellado, L Alcázar-Fuoli <i>NOTE: This abstract has also been selected for Oral Presentation</i>	107
38	<i>Aspergillus fumigatus</i> and <i>Pseudomonas aeruginosa</i> pulmonary co-exposure results in increased IL-17A, eosinophilia, and acute lung injury in allergic animals BN Steffan*, SA Hoselton, NP Keller, JM Schuh	108
39	Phagocytosis of Mucorales spores by lung epithelial cells and macrophages U Binder*, V Naschberger, C Lass-Flörl, D Wilflingseder	109
40	Evaluating the role of STAT3 in CD4+ T cells in susceptibility to invasive aspergillosis W Gohir*, L McTaggart, J Kus, T Mazzulli, D Kumar, A Humar, S Husain	110
41	Epithelial uptake of <i>Aspergillus fumigatus</i> spores drives efficient fungal clearance in vivo and is aberrant in Chronic Obstructive Pulmonary Disease (COPD) patients M Bertuzzi*, GJ Howell, R Fortune-Grant, X Du, J Smith, DD Thomson, L Gregson, BA Greser, NC Motsi, N Van Rhijn, M Demirbag, EM Bignell <i>NOTE: This abstract has also been selected for Oral Presentation</i>	111

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER #	ABSTRACT & AUTHORS	PAGE
42	<i>Aspergillus fumigatus</i> cell wall promotes apical airway epithelial recruitment of human neutrophils MB Feldman, RA Dutko, M Wood, RA Ward, HM Leung, RF Snow, DJ de la Flor, LM Yonkers, JL Reedy, GJ Tearney, H Mou, B Hurley, JM Vyas*	112
43	The antigens enolase, triosephosphate isomerase and heat shock protein HSS1 of <i>Mucor circinelloides</i> are recognized by sera from immunocompromised infected mice M Areitio, A Martin-Vicente, A Arbizu, A Antoran, L Aparicio-Fernandez, I Buldain, L Martin-Souto, X Guruceaga, A Rementeria, J Capilla, FL Hernando, A Ramirez-Garcia*	113
44	An immunoproteomics approach to identify <i>Aspergillus fumigatus</i> protein antigens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis (ABPA) J Macheleidt, J Kruse, P Bacher, C Grehn, A Scheffold, C Schwarz, J Springer, J Löffler, H Einsele, O Kniemeyer*, A Brakhage	115
45	“Invasive aspergillosis on-a-chip” – a novel disease model to study <i>Aspergillus fumigatus</i> infection in the human lung TNM Hoang, Z Cseresnyés, S Hartung*, K Rennert, MT Figge, AS Mosig, M von Lilienfeld-Toal <i>NOTE: This abstract has also been selected for Oral Presentation</i>	116
46	Single cell approaches reveal the key dendritic cell subsets that coordinate allergic airway inflammation against the fungal allergen <i>Aspergillus fumigatus</i> P Cook*, S Brown, E Houlder, S Khan, G Tavernier, F Svedberg, M Bertuzzi, C Forss, JE Allen, E Newell, E Bignell, A Simpson, R Niven, D Denning, A MacDonald <i>NOTE: This abstract has also been selected for Oral Presentation</i>	117
47	Mycobacterial modulation of macrophages response to <i>Aspergillus fumigatus</i> LE Gonzales-Huerta*, T Williams, CA Evans, D Armstrong-James	118
48	Recognition of <i>Aspergillus fumigatus</i> galactomannan by the C-type lectin receptor dectin-2 JL Reedy*, PE Negoro, T Fontaine, H Wang, NS Khan, RA Dutko, MK Mansour, M Wuthrich, JP Latge, JM Vyas	119
49	Uncoupling of cytokine signaling and LC3 associated phagocytosis (LAP) drives the development of invasive aspergillosis in patients with sepsis T Akoumianaki*, R Beau, F Pene, FL van de Veerdonk, K Vaporidi, M Netea, JP Latge, G Chamilos <i>NOTE: This abstract has also been selected for Oral Presentation</i>	120
50	Human MAIT cells as a new player in the immune response against filamentous fungi S Boettcher, S Hartung, MM Ruethrich*, M von Lilienfeld-Toal, S Jahreis	122
51	Vaccine-induced immunogenicity and protection in a murine model of invasive pulmonary aspergillosis E Rayens*, W Rabacal, SE Kang, K Norris <i>NOTE: This abstract has also been selected for Oral Presentation</i>	123
52	Immunomodulatory properties of antifungals on human monocytes: an exploratory study B Henry*, W Gohir, D Kumar, A Humar, C Aguilar, S Husain	124

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER #	ABSTRACT & AUTHORS	PAGE
53	Modelling epithelial cell – macrophage communication in fungal allergy S Gago*, D Weaver, M Bromley, D Denning, P Bowyer	126
54	Antifungal liposomes targeted to fungal cells have dramatically increased efficacy RB Meagher*, ZA Lewis, X Lin, M Momany, S Ambati	127
55	Why are mucormycetes resistant against voriconazole? M Lackner*, M V Keniya, B C Monk <i>NOTE: This abstract has also been selected for Oral Presentation</i>	128
56	Transcription factor HSF1 decreases the expression of surfactant protein-D in cells infected with <i>Aspergillus fumigatus</i> SS Kim, HJ Kim*, GS Shin	129
57	<i>Aspergillus</i> section <i>Fumigati</i> molds: A model lineage for studying the repeated evolution of fungal pathogenicity ME Mead*, JL Steenwyk, HA Raja, SL Knowles, LP Silva, GH Goldman, NH Oberlies, A Rokas	130
58	Monitoring of mucormycosis and drug efficacy testing by the use of <i>M. circinelloides</i> reporter strains U Binder*, MI Navarro-Mendoza, FE Nicolas, V Naschberger, C Kandelbauer, I Bauer, J Pallua, C Lass-Flörl, V Garre	131
59	The negative cofactor 2 complex is a master regulator of drug resistance in <i>Aspergillus fumigatus</i> T Furukawa*, N Van Rhijn, F Gsaller, M Fraczek, S Paul, J Parker, S Kelly, R Cramer, J Latge, S Moye-Rowley, E Bignell, P Bowyer, M Bromley <i>NOTE: This abstract has also been selected for Oral Presentation</i>	132
60	The protein kinase A-dependent phosphoproteome of <i>Aspergillus fumigatus</i> reveals novel kinase targets associated with diverse and essential cellular pathways EK Shwab*, PR Juvvadi, S Shaheen, J Allen, G Waitt, EJ Soderblom, BG Bobay, YG Asfaw, MA Moseley, WJ Steinbach	133
61	Identification of azole resistance mechanisms in <i>Aspergillus lentulus</i> A Martin-Vicente*, A Nywening, ACO Souza, W Ge, K Datta, KA Marr, NP Wiederhold, JR Fortwendel	135
62	Investigation of the molecular mechanisms of copper homeostasis in <i>Aspergillus fumigatus</i> Y Kusuya*, B Cai, D Hagiwara, T Yaguchi, H Takahashi	136
63	<i>In vivo</i> competitive fitness profiling reveals protein kinases required for drug tolerance and adaptation of <i>Aspergillus fumigatus</i> to the murine host environment C Zhao, N Alfuraiji, H Alshammri, E Bignell, M Bromley*	137
64	CRISPR-Cas9 mutation and characterization of the most overexpressed transcription factor of swollen state of <i>Aspergillus fumigatus</i> U Perez-Cuesta*, X Gुरुcega, A Ramirez-Garcia, FL Hernando, A Abad-Diaz-de-Cerio, A Rementeria	138
65	Biosynthesis of alpha-amino-β-hydroxybutanoyl-glycyluridine: a key component in antifungal nucleoside antibiotics S Malek Zadeh*, TL Li	139

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER #	ABSTRACT & AUTHORS	PAGE
66	Efficacy and safety of high-dose caspofungin in the salvage therapy of pulmonary aspergillosis YK Jiang, LP Huang, CW Yip, JH Cheng, CX Que, HZ Zhao, X Wang, LP Zhu, LH Zhou*	140
67	Incidence of cutaneous squamous cell carcinoma in patients receiving voriconazole therapy for chronic pulmonary aspergillosis C Kosmidis*, A Mackenzie, C Harris, R Hashad, F Lynch, DW Denning	141
68	Accumulation of a novel inhaled azole, PC945, in alveolar cells in temporally neutropenic immunocompromised mice infected with <i>Aspergillus fumigatus</i> K Ito*, Y Kizawa, G Kimura, Y Nishimoto, G Rapeport, P Strong	142
69	Effects of inhaled PC945 on fungal load in mouth wash collected from healthy subjects in the first-in-human study (NCT02715570) L Daly*, K Woodward, M Coates, L Cass, P Strong, A Murray, G Rapeport, K Ito	143
70	Topical liposomal amphotericin B (AmBisome®, Gilead Sciences Ltd, Abington, United Kingdom) as an adjunctive therapy in the management of post-traumatic invasive fungal infection (IFI) A Bapat*, C Eades, L Jones, J Cruise, K Hossenbaccus, B Cherian	144
71	Gallium as an anti-<i>Aspergillus</i> antifungal DA Stevens*, M Martinez, L Yee, J Woo, V Truong, MO Xavier	146
72	The UK National Aspergillosis Centre – Ten years’ service C Harris*, B Bradshaw, GT Atherton, H Findon, DW Denning	147
73	ROS-dependent and independent host-induced fungal regulated cell death in defense against invasive aspergillosis N Shlezinger*, TM Hohl <i>NOTE: This abstract has also been selected for Oral Presentation</i>	148
74	Interdependency of host and pathogen protein persulfidation governs disease severity in experimental and human aspergilloses M Sueiro-Olivares, S Gago, J Scott, Y Yu, M Strobel, C Cunha, E Kouroussis, J Zivanovic, D Thomson, P Bowyer, A Beilhack, A Carvalho, MR Filipovic, E Bignell, J Amich* <i>NOTE: This abstract has also been selected for Oral Presentation</i>	149
75	In high iron environment, pyocyanin is a major anti-<i>Aspergillus</i> molecule P Chatterjee*, G Sass, H Nazik, E Déziel, DA Stevens	150
76	Palmitolealdehyde targeting conidial pigmentation and surface morphology in <i>Aspergillus fumigatus</i> S Hoda*, L Gupta, P Vijayaraghavan	151
77	Phenotypic analysis of <i>Aspergillus fumigatus</i> mutant lacking the P-type Na⁺-ATPase encoding gene <i>enaA</i> T Wittayaprapharat*, S Foongladda, N Pinchai	152
78	Regulatory control of epithelial damage during <i>Aspergillus fumigatus</i> infection SR Khan*, Z Carter, L Gregson, D Thomson, N Van Rhijn, P Papastamoulis, M Rattray, M Bromley, E Bignell	153

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER #	ABSTRACT & AUTHORS	PAGE
79	Iron overload decreases macrophage lysosomal acidification, impairing the clearance of <i>Aspergillus fumigatus</i> conidia MR Kaji*, EI Matthaiou, OV Manouvakhova, JL Hsu <i>NOTE: This abstract has also been selected for Oral Presentation</i>	154
80	Phagosomal removal of fungal melanin reprograms macrophage metabolism to promote antifungal immunity SM Gonçalves*, C Duarte-Oliveira, V Aimaniananda, D Antunes, G Chamilos, FL van de Veerdonk, MG Netea, JP Latgé, C Cunha, A Carvalho <i>NOTE: This abstract has also been selected for Oral Presentation</i>	155
81	Human lung colonization enables parasexual recombination in <i>Aspergillus fumigatus</i> T Engel, PE Verweij, J van den Heuvel, D Wangmo, J Zhang, AJM Debets, E Snelders*	156
82	Mucoricin is a Mucorales ricin-like toxin critical for mucormycosis pathogenesis SS Soliman, C Baldin, Y Gu, S Singh, T Gebremariam, M Swidergall, A Pikoulas, C Perske, V Venkataramani, VM Bruno, JE Edwards, Jr, SG Filler, G Chamilos, ES Vitetta, AS Ibrahim* <i>NOTE: This abstract has also been selected for Oral Presentation</i>	157
83	<i>Aspergillus fumigatus</i> – <i>Stenotrophomonas maltophilia</i> co-inoculation model on bronchial epithelial cells: antibiosis effect and inflammatory response according to bacterial strains C Courboulès*, E Melloul, V Balloy, L Roisin, PL Woerther, J Guillot, E Dannaoui, F Botterel	158
84	Genetic polymorphism and mating type of <i>Aspergillus fumigatus</i> strains isolated from cystic fibrosis patients A Rolland, J Bigot, F Botterel, C Hennequin, J Guitard*	159
85	The integral membrane protein stomatin plays an important role in phagocytosis of <i>Aspergillus fumigatus</i> conidia M Goldmann*, F Schmidt, S Jahreis, S Hartung, M Lilienfeld-Toal, T Heinekamp, AA Brakhage	160
86	Inhibitory effect of α-bisabolol on gliotoxin production in <i>Aspergillus fumigatus</i> Af293 Z Jahanshiri*, F Asghari-Paskiabi, M Razzaghi-Abyaneh	161
87	Genetically distinct transcriptional circuits drive stress-adaptation and host cytotoxicity in the major mould pathogen of the human lung N van Rhijn*, T Furukawa, SR Khan, P Papastamoulis, F Rodenburg, R Fortune-Grant, M Rattray, M Bromley, E Bignell	162
88	<i>Aspergillus flavus</i> biomass in maize and use of a biocontrol strategy to limit aflatoxin production AO Mitema*, SM Rafudeen, NA Feto, S Okoth	163
89	Ubiquity, diversity, and functional genomics of Mucoromycota and their Betaproteobacterial endosymbionts J Uehling*, D Carter-House, S Putumbaka, J Stajich, J Spatafora, G Bonito, R Vilgalys <i>NOTE: This abstract has also been selected for Oral Presentation</i>	164
90	Characterization of G-protein coupled receptor NopA in <i>Aspergillus fumigatus</i> Y Choi*, S Yoon, KS Shin	166
91	A novel resistance mechanism to calcineurin inhibitors in <i>Mucor circinelloides</i> S Vellanki*, RB Billmyre, A Lorenzen, M Campbell, B Turner, EY Huh, J Heitman, SC Lee	167

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER #	ABSTRACT & AUTHORS	PAGE
92	Virus infection of <i>Aspergillus fumigatus</i> (Af) compromises Af in intermicrobial competition H Nazik, I Kotta-Loizou, DA Stevens* <i>NOTE: This abstract has also been selected for Oral Presentation</i>	168
93	<i>Aspergillus fumigatus</i> KnrA is an intrinsically disordered protein and functions as a potential substrate of calcineurin and protein kinase A in the cell wall integrity pathway PR Juvvadi*, EK Shwab, BG Bobay, DC Cole, J Allen IV, S Shaheen, G Waitt, EJ Soderblom, MA Moseley, YG Asfaw, WJ Steinbach <i>NOTE: This abstract has also been selected for Oral Presentation</i>	169
94	Analysis of <i>cyp51A</i> polymorphisms of <i>Aspergillus fumigatus</i> in Japan H Majima*, T Arai, A Watanabe, T Yaguchi, Y Miyazaki, K Kamei	170
95	Pathogenic allopolyploid hybrids of <i>Aspergillus</i> fungi JL Steenwyk*, AL Lind, LNA Ries, TF dos Reis, LP Silva, F Almeida, RW Bastos, F Rodrigues, K Lagrou, GH Goldman, A Rokas	171
96	The deletion of <i>idoC</i> gene in <i>Aspergillus fumigatus</i> affects its normal growth and resistance to different stresses X Guruceaga*, U Perez-Cuesta, A Martin-Vicente, A Abad-Diaz-de-Cerio, FL Hernando, JR Fortwendel, A Ramirez-Garcia, A Rementeria	172
97	Epigenetic mechanisms of azole stress adaptation in <i>Aspergillus fumigatus</i> M Aruanno*, S Gozel, D Bachmann, JE Parker, A Coste, D Sanglard, F Lamothe	173
98	Investigation of adaptation to hypoxia in <i>Aspergillus fumigatus</i> C Bian*, Y Kusuya, D Hagiwara, A Watanabe, H Takahashi	174
99	Study on gene expression of Na⁺-ATPase encoding gene <i>enaA</i> during stress response in <i>Aspergillus fumigatus</i> N Pinchai*	175
100	Navigating barriers to understand early endosome trafficking in <i>Aspergillus fumigatus</i> BD Bieger*, AM Rogers, MJ Egan	176
101	Fungal contamination rates of water in Lagos University Teaching Hospital water distribution systems KS Olawale*, FT Ogunsola, RF Peters, RO Oladele, DW Denning	177
102	Probable hospital sources of <i>Aspergillus</i> species isolated from bedfast cases K Diba*, N Moshiri, M Rabiepour, F Jangi	178
103	Allergic bronchopulmonary aspergillosis, <i>Aspergillus fumigatus</i> chronic colonization and cystic fibrosis transmembrane conductance regulator genotype; a complicated relationship in cystic fibrosis patients M Noni*, A Katelari, S Doudounakis, V Spoulou	179
104	The clinical spectrum of <i>Aspergillus fumigatus</i> diseases in cystic fibrosis M Noni*, A Katelari, S Doudounakis, V Spoulou	180
105	<i>Aspergillus terreus</i> infection in a patient with cardiac implantable electronic device AB Xess*, R Bir, G Singh, I Xess	181

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER #	ABSTRACT & AUTHORS	PAGE
106	Mucormycosis: Emerging and devastating fungal infection, continuing further one-year experience from tertiary care hospital, northern India J Chander*, N Singla, N Gulati, A Bhagat, G Dhanda, RPS Punia, D Aggarwal, AK Attri, A Dass	182
107	Clinical spectrum and antifungal susceptibility profile of <i>Aspergillus terreus</i> species complex: a single centre study from India G Singh*, I Xess, P Mani, A Iram, J Sachdev, A Xess, A Mohan, M Soneja, R Seth	184
108	Prevalence of <i>Aspergillus fumigatus</i> and <i>Aspergillus flavus</i> in soil of agricultural fields in Nepal U Shrestha Khwakhali*	185
109	Diagnosis of female genital tuberculosis using Xpert MTB/RIF SK Dhami*, HS Bisht	186
110	Clinical evaluation of chronic pulmonary aspergillosis in patients with nontuberculous mycobacterial lung disease JS Suzuki*, KT Takeda, ON Narumoto, HN Nagai, HM Matsui	187
111	Re-administration of voriconazole after hepatic toxicity O Narumoto*, J Suzuki, K Takeda, A Tamura, H Nagai, H Matsui	188
112	Fungal burden in a Clinical Pathology Service of a Central Hospital in Lisbon AQ Gomes*, B Almeida, R Lourenço, M Dias, LA Caetano, C Viegas	189
113	An exotic case of palatal entomophthoromycosis due to <i>Conidiobolus coronatus</i> V Hallur, M Sable, G Purohit, P Parida, V Deshmukh*	190
114	The incidence of pulmonary aspergillosis in patients with cystic fibrosis in Russian Federation YI Kozlova, YV Borzova, TA Stepanenko, AV Orlov, OV Aak, TS Bogomolova, SM Ignatyeva, NV Vasilyeva, NN Klimko* <i>NOTE: This abstract has also been selected for Oral Presentation</i>	191
115	A difficult-to-treat case of mucormycosis S Kömür*, S Paydaş, M Dağkiran, A Uğuz, B Kurtaran	192
116	New perspective: evaluation of mucormycosis cases with European QUALITY (EQUAL) score S Kömür*, A Ulu, A Uğuz, AS İnal, F Kuşcu, M Dağkiran, HD Dinçyürek, B Kurtaran, Y Taşova	193
117	Prospective evaluation of quality of life and <i>Aspergillus</i> IgG in tuberculosis (TB) patients in Lagos, Nigeria RO Oladele*, T Gbajabiamila, FT Ogunsola, R Longe-Peters, S Skevington, DW Denning <i>NOTE: This abstract has also been selected for Oral Presentation</i>	194
118	Fatal mucormycosis and aspergillosis in an atypical host: what do we know about mixed invasive mold infections? DF Farmakiotis*, WC Cao, JD Donahue	195
119	<i>Aspergillus fumigatus</i> rhinocerebral abscess in a diabetic patient D Pinheiro*, C Monteiro, E Pinto	197
120	Environmental distribution of <i>Aspergillus terreus</i> species complex in Tyrol, Austria AM Dietl*, R Vahedi-Shahandashti, C Lass-Flörl	198

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER #	ABSTRACT & AUTHORS	PAGE
121	Environmental <i>Aspergillus</i> and Mucorales species in beach-sand of Israeli Mediterranean coast: possible impact on human health M Frenkel, Y Yunik, S Blum, D Elad, E Sionov, E Segal*	199
122	Design of a phase 2 study to evaluate fosmanogepix (APX001), a novel antifungal, for the treatment of patients with invasive mold infections (IMI) with limited treatment options MR Hodges*, J Maertens, BJ Kullberg, JR Perfect, SE Hazel, H Schlamm, OA Cornely	200
123	Clinical and microbiological characterization of influenza associated aspergillosis in Southern Taiwan HC Wang, CT Cia, MI Hsieh, PC Chou, CJ Wu*, WC Ko <i>NOTE: This abstract has also been selected for Oral Presentation</i>	201
124	Using social media to expand the impact of LIFE Worldwide in fungal medical education BH Bradshaw*, GT Atherton, H Findon, C Harris, DW Denning, JL Rodriguez Tudela	202
125	Disseminated invasive aspergillosis. Results of retrospective analysis of the large register O Shadrivova, S Khostelidi, E Desyatik, E Shagdileeva, O Uspenskaya, M Popova, A Volkova, Y Borzova, T Bogomolova, S Ignatyeva, L Zubarovskaya, B Afanasyev, N Vasilyeva, N Klimko*	203
126	Clinical and laboratory features of invasive aspergillosis in HIV-positive patients O Shadrivova, O Leonova, D Bubnova, A Volkova, M Popova, T Bogomolova, S Ignatyeva, L Zubarovskaya, B Afanasyev, N Vasilyeva, N Klimko*	204
127	Invasive aspergillosis in adult non-hematological patients O Shadrivova, M Tonkoshkur, E Desyatik, A Volkova, M Popova, S Ermolova, T Bogomolova, S Ignatyeva, L Zubarovskaya, B Afanasyev, N Vasilyeva, N Klimko*	205
128	Clinical and laboratory features of invasive aspergillosis in patients with multiple myeloma O Shadrivova, V Pivovarova, Y Chudinovskikh, T Shneyder, O Uspenskaya, M Popova, A Volkova, E Desyatik, Y Borzova, S Ignatyeva, T Bogomolova, L Zubarovskaya, B Afanasyev, N Vasilyeva, N Klimko*	206
129	The combination of invasive aspergillosis with other mycoses in adult hematologic patients O Shadrivova, S Khostelidi, E Shagdileeva, Y Chudinovskikh, M Popova, A Volkova, E Desyatik, S Ignatyeva, T Bogomolova, L Zubarovskaya, B Afanasyev, N Vasilyeva, N Klimko*	207
130	Invasive aspergillosis in elderly patients O Shadrivova, S Khostelidi, E Desyatik, A Volkova, M Popova, O Uspenskaya, T Shneyder, T Bogomolova, S Ignatyeva, L Zubarovskaya, B Afanasyev, N Vasilyeva, N Klimko*	208
131	Cases of successful treatment of chronic pulmonary aspergillosis in patients after destructive pneumonia M Zakhvatkina, O Shadrivova, E Desyatik, N Nikolaeva, Y Borzova, T Bogomolova, S Ignatyeva, N Vasilyeva, N Klimko*	209

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER #	ABSTRACT & AUTHORS	PAGE
132	Mucormycosis in large cohort of pediatric and adult patients after hematopoietic stem cell transplantation & chemotherapy M Popova*, Y Rogacheva, A Volkova, A Frolova, I Markova, A Shvetcov, I Nikolaev, S Ignatieva, T Bogomolova, A Gevorgayn, O Paina, T Bykova, E Darskaya, O Goloshchapov, M Vladovskaya, S Bondarenko, I Moiseev, L Zubarovskaya, N Klimko, B Afanasyev	210
133	Features of invasive aspergillosis in B-cell lymphoma patients: risk factors, diagnostics, treatment and survival J Chudinovskikh, T Semiglazova, M Popova, O Shadrivova, I Zuzgin, S Ignatyeva, T Bogomolova, L Filatova, E Cherkasova, N Klimko*	211
134	Case of successful treatment of invasive aspergillosis in girl with systemic lupus erythematosus O Kozlova, M Kostik, P Muratov, T Bogomolova, S Ignatieva, N Klimko*	212
135	Invasive aspergillosis in pediatric patients with malignancies: retrospective register review Y Dinikina, O Shadrivova, M Belogurova, S Ignatyeva, T Bogomolova, E Boichenko, N Klimko*	213
136	Chest computed tomography (CT) scan features of chronic pulmonary aspergillosis (CPA) NG Nikolaeva*, OV Shadrivova, NN Klimko	214
137	The global impact of <i>Aspergillus</i> infection on COPD E Hammond*, C McDonald, J Vestbo, DW Denning	215
138	Systemic aspergillosis secondary to acute enterocolitis in foals M Mousquer, RP Souza, L Rafael, J Bonel, AM Melo*, AG Reis, RO Faria, DA Stevens, MO Xavier, CEW Nogueira	216
139	Rhinocerebral mucormycosis in a newly diagnosed type I diabetic: a case report at a tertiary facility in Northern Nigeria J Ejembi*, IM Adeyemo, I Okpe, HM Umar, F Bello, AG Bakari, O Jimoh, AT Olayinka	217
140	A case of invasive pulmonary aspergillosis occurring in a non-neutropenic patient at a tertiary facility in North-West Nigeria J Ejembi*, M Abdulazeez, R Oladele, I Gembu, AT Olayinka, AI Mamman	218
141	<i>Aspergillus</i> keratitis in the center of Tunisia: a 37-year retrospective study S Ismail, H Chouaieb, A Yaacoub, M Ben Saif, M Ben Said, A Fathallah*	220
142	Epidemiological trends in <i>Aspergillus</i> spectrum involved in human aspergillosis in Sousse region, Tunisia: a 33-year retrospective study (1986-2019) H Chouaieb, S Ismail, M Ben Saif, A Yaacoub, Y Bahri, F Saghrouni, M Ben Said, A Fathallah*	221
143	Pulmonary mucormycosis in diabetic patients: a report of 4 cases I Dhib, A Yaacoub, F Belazreg, S Ismail, A Letaief, H Hmouda, A Fathallah*	222
144	Rhinocerebral mucormycosis in central Tunisia: a study of 15 cases I Dhib, A Yaacoub, H Chouaib, S Ismail, M Bellakhdhar, A Garrouche, M Abdelkefi, A Fathallah*	223
145	Various clinical forms of ear mucormycosis: report of four cases A Yaacoub, Y Barhi, A Meherzi, H Chouaib, W Kermani, M Abdelkefi, A Fathallah*	224

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER #	ABSTRACT & AUTHORS	PAGE
146	Primary cutaneous aspergillosis: report of two cases S Ismail, A Yaacoub, H Chouaieb, H Regaieg, N Ben Sayed, N Abdessayed, W Hachfi, Y Ben Youssef, M Mokni, A Letaief, A Khlif, A Fathallah*	225
147	Galactomannan detection in bronchoalveolar lavage fluids: a diagnostic approach for fungus ball in patients with pulmonary tuberculosis? MT Hedayati*, M Gheisari, N Basharadz, J Yazdani Charati, MS Mirenayat, M Pourabdollah, S Ansari, V Mortezaee, M Abastabar, J Jafarzadeh, I Haghani	226
148	PCR based methods for diagnosis of mucormycosis M Pandey*, R Agarwal, G Singh, R Kumar, V P Jyotsna, A Iram, P Mani, A Xess, I Xess	228
149	Mucorales-specific quantitative PCR on peripheral blood is a sensitive and early diagnostic marker for invasive mucormycosis T Mercier*, M Reynders, K Beuselinck, E Guldentops, J Maertens, K Lagrou	229
150	Defining new risk factors for <i>Aspergillus</i> bronchitis S Gago*, D Weaver, S Anees-Hill, C Harris, CB Moore, MD Richardson, MJ Bromley, P Bowyer, DW Denning	231
151	A high frequency of azole resistance due to G54 mutations in <i>Aspergillus fumigatus</i> from bronchoalveolar lavage of chronic respiratory diseases patients in a referral chest hospital in Delhi, India using the AsperGenius® Resistance real-time PCR assay and a new G54/M220 assay A Singh*, KK Mahto, PK Singh, K Jain, JF Meis, A Chowdhary	232
152	Mitochondrial markers a future direction for the detection, identification and quantification of mucormycetes? R Caramalho, L Madl, K Rosam, G Rambach, C Speth, J Pallua, T Larentis, R Araujo, A Alastruey-Izquierdo, C Lass-Flörl, M Lackner*	233
153	Evaluation of serum <i>Aspergillus</i> IgG level in pulmonary tuberculosis patients in Indonesia F Setianingrum*, A Rozaliyani, R Adawiyah, R Syam, M Tugiran, CYI Sari, F Nandipinto, J Ramnath, D Handayani, E Burhan, MC Rumende, AR Arifin, R Wahyuningsih, RR Richardson, DW Denning	234
154	Molecular detection of <i>Aspergillus</i> in respiratory samples collected from patients with suspicion of respiratory fungal infection M Oliveira, H Simões, C Veríssimo, R Sabino*	236
155	Validation of diagnostic criteria in pathological or physician-diagnosed cases with allergic bronchopulmonary aspergillosis/mycosis KA Asano*, HA Hebisawa, TI Ishiguro, NT Takayanagi, JS Suzuki, JT Tanaka, MT Taniguchi, KK Kamei, TO Oguma	237
156	Local experience feedback on performing routinely the PCR Mucorales on blood samples in hematological patients AP Bellanger*, A Berceanu, E Scherer, E Daguindeau, Y Desbrosses, L Millon	239
157	Development of main spectral profiles database for MALDI-identification of common aspergillosis causative agents from the colonies obtained in liquid medium NV Vasilyeva*, IA Riabinin, LV Alieva, YV Mikhaylova, YV Borzova, TV Bogdanova, AY Alexeyev, NP Remnyeva, VM Kaschuba, OA Schurpitskaya, TS Bogomolova, GA Chilina	240

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER #	ABSTRACT & AUTHORS	PAGE
158	Relationship between clinical and environmental <i>Aspergillus</i> isolates from the high-risk areas of a tertiary care hospital I Xess*, M Mahapatra, P Mani, G Singh, A Mohan, R Kumar, S Bakshi, M Soneja, M Pandey	242
159	Multiplex real time PCR for detection and identification of <i>Aspergillus</i> and <i>Mucormycetes</i> spp. in native and formalin-fixed paraffin-embedded tissue samples of patients with mycosis SM Ignatyeva*, VA Spiridonova, TS Bogomolova, YL Avdeenko, OV Shadrivova, YV Borzova, IS Zuzgin, JA Chudinovskikh, MO Popova, OS Uspenskaya, NN Klimko, NV Vasilyeva	243
160	Adaptation of a quantitative mucormycosis PCR to a fast-protocol for a same-day result AT Coste*, R Brouillet, Z Naseri, K Jaton	244
161	The potential of early low-dose chest computed tomography (CT) plus pulmonary angiography (CTPA) to improve management of invasive mould disease (IMD) in high-risk patients with hematological malignancies: a pilot study M Stanzani*, C Sassi, C Sartor, G Battista, PE Coppola, RE Lewis	245
162	Establishment of a whole blood ELISA to quantify T-cellular cytokine release in response to <i>Aspergillus fumigatus</i> antigens CD Lauruschkat*, L Page, S Etter, E Schnack, F Ebel, J Loeffler, S Wurster	246
163	Etanercept treatment and monocytopenia increase the risk for invasive aspergillosis in patients after allogeneic stem cell transplantation T Zoran*, M Weber, J Springer, PL White, J Bauer, A Schober, C Löffler, B Seelbinder, K Hünninger, O Kurzai, A Scherag, S Schäuble, CO Morton, H Einsele, J Linde, J Löffler	247
164	Burden of serious fungal infections in Togo AM Dorkenoo, BK Ocansey*, E Sossou, F Lack, A Adjetey-Toglozombio, DW Denning	248
165	NIAID Resources Poster D Love	249